Business Wire

MA-ANTERRA-CAPITAL

18.5.2022 07:02:06 CEST | Business Wire | Press release

Share
Anterra Capital: Pandemic and Food Price Inflation Fuel Investor Interest to Accelerate Transformation of the Food and Ag Sector

A crushing pandemic and, more recently, the Ukraine war have convinced investors more than ever that the world needs to radically change how it produces, distributes and consumes food, says Adam Anders, managing partner of the international food and agriculture specialist venture capital firm Anterra Capital (“Anterra”).

Anders: “The pandemic highlighted the fragility and adverse health impacts of our current food system: soaring prices, empty shelves in stores; the fact that unhealthy diets are a major risk factor for getting Covid; that the way we treat farm animals could trigger the next pandemic. Post our final closing, the devastating impact of the Ukraine War on the global food supply has increased the awareness among investors even further. This, plus our focus on deploying proven biotech and digital solutions to shake up the lagging Food and Ag-sector, go a long way in explaining the higher than expected interest in our second fund.”

Anterra is proud to announce the closing of its second fund, with commitments in excess of $260 million. All investors from Anterra’s first fund returned in Fund II, led by Rabo Investments and Eight Roads Ventures. This fund also welcomes an international influx of new investors, ranging from pension funds and sovereign wealth funds to family offices and tech entrepreneurs from other sectors.

Anders: ”A new crop of mainstream investors is ready to get involved. Many already believed that the advances of the Green Revolution came at a hefty price. It gave us cheap fertilizer and powerful pesticides for growing plants; and growth hormones and antibiotics in animal production. But its obsession with yield is also destroying ecosystems and our own health. The pandemic gave the final push. Investors realize they can help build a resilient and regenerative food system and make excellent returns at the same time.”

One other unexpected outcome of the pandemic is that it has changed the outlook for using biotech in food and ag. Traditionally, this has been met with substantial public resistance. But since the roll-out of mRNA vaccines, billions of people have witnessed the positive power of biotech firsthand.

Anders: “Growing public acceptance of biotech solutions and gene-editing thanks to mRNA-vaccines, is an important shift. Biotech advances will also play a critical role in making food and agriculture more resilient and less carbon intensive; from fighting and preventing infectious diseases that jump from animals to humans; to developing more sustainable crop health solutions.”

Anterra believes that biotech and digital solutions are the two key technologies that will transform the food and agricultural sector. Through this technological lens Anterra seeks out entrepreneurs across the value-chain, ranging from ag fintech, crop science and animal health to human nutrition and consumer tech. Where it feels opportunities are being missed, Anterra also incubates companies itself: since 2018, Anterra has built five successful start-ups from scratch. At the same time, technology does not have to be cutting-edge to make its mark in the sector.

Anders: “Technology-wise food and ag lags 20 years behind sectors like human health and banking, so you don’t necessarily need the latest, cutting edge technology to transform it. Our incubated companies focus on deploying biotech and digital solutions that are established elsewhere, but are new to food and ag. I can confidently say we are unique in that approach. It’s an advantage of operating in a slow-moving sector: you can innovate in a slightly de-risked way.”

Executing this strategy, Anterra has built a diverse portfolio of innovators, ranging from entrepreneurs developing the next generation of targeted pesticides with low environmental impact, like Enko and Vestaron; start-ups improving animal and human health, like Invetx, Animol and Caribou Biosciences (co-founded by Nobel-prize winner Jennifer Doudna); companies empowering farmers with field data, access to finance, transparent pricing and direct distribution channels, like ProducePay and Agriconomie; and consumer tech-driven businesses transforming how we choose, buy and think about food, like LaFourche and Lollipop.

Anders: “Our strategy and years of experience are paying off. We look forward to supporting the next generation of great entrepreneurs and building a better food system.”

About Anterra
With offices in Amsterdam and Boston, Anterra Capital is an international specialist venture capital investor dedicated to financing the growth of technology-driven companies with incredible potential in food, agriculture, and animal health. Supported by multinational institutional investors, family offices and like-minded entrepreneurs, Anterra provides patient strategic capital to innovative companies sustainably transforming our global food system. Further information: www.anterracapital.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

VELOCIFERO Takes Action Against Counterfeiting in China13.11.2026 17:32:00 CET | Press release

White s.r.o., exclusive owner of the VELOCIFERO brand, takes action in China to protect its intellectual property rights. Initial measures in Chongqing and Taizhou have already resulted in the seizure of vehicles alleged to be counterfeit. VELOCIFERO is taking action against counterfeiting in China. White s.r.o., the exclusive owner of the VELOCIFERO brand and its related intellectual property rights, has launched decisive measures to protect its creative and industrial assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113797570/en/ Photo courtesy of White s.r.o. “Vehicle sealed in Chongqing as part of actions undertaken to protect VELOCIFERO’s intellectual property rights.” The matter originated in June 2026 when, according to the company’s complaint, computers were removed from the technical office of Taizhou Siweiluo, the company appointed to manufacture VELOCIFERO products. White s.r.o. subsequently became aware

LangChain Raises $300M to Enable Every Company to Own Their Intelligence13.11.2026 16:53:00 CET | Press release

CapitalG leads Series C funding round at a $3B valuation to advance LangChain's agent engineering platform LangChain today announced it has raised $300 million in new funding at a $3 billion valuation, bringing total funding to date to $460 million. The round was led by existing investor CapitalG, with significant participation from new investors GIC and DFJ Growth and existing investors IVP and Sapphire Ventures. LangChain is advancing its mission to help every company own its intelligence. As agents transform the economy, companies are building domain-specific agents differentiated by their knowledge, data, and user experience. These agents will power new products and transform internal company operations, creating lasting competitive advantages for the companies that control them. "Agents are going to transform how companies operate and the products they deliver. The companies that control these systems will build lasting competitive advantages," said Harrison Chase, Co-Founder and

Kinaxis Named a Leader in Five 2026 IDC MarketScapes for Worldwide Supply Chain Planning13.11.2026 13:00:00 CET | Press release

Maestro delivers concurrent planning on a single platform across discrete, process, consumer packaged goods and life sciences Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced it has been named a Leader in five 2026 IDC MarketScape vendor assessments for worldwide supply chain planning. The recognition spans the overall market and four industries - discrete industries, process industries, consumer packaged goods and life sciences industries - all served by a single platform, Kinaxis Maestro®, the company's AI-powered supply chain orchestration platform. "Supply chain leaders don't need a better forecast once a month. They need to know what changed this morning, what it means across the business, and what to do about it," said Andrew Bell, Chief Product Officer of Kinaxis. "I believe being named a Leader across five IDC MarketScape vendor assessments, in industries that plan in very different ways, shows that a single concurr

SBC Medical Announces Capital and Business Alliance with NeuroBrain Dynamics to Advance Clinic Profitability Through Medical AI13.11.2026 12:30:00 CET | Press release

Companies to co-develop six medical AI solutions targeting revenue expansion and cost reduction; SBC Medical secures priority sales rights in Japan and South Korea and targets B2B expansion across Asia SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced a strategic capital and business alliance agreement with NeuroBrain Dynamics Inc. (“NBD”), a Taipei-based company dedicated to enterprise generative AI solutions. As part of the agreement executed on November 13, 2026, SBC Medical has made a minority equity investment in NBD. Through this alliance, SBC Medical plans to introduce two complementary suites of generative AI solutions across its network of 287 clinics in Japan and overseas*: “revenue-growth AI,” to elevate average revenue per visit and customer retention through personalized customer guidance, and “cost-reduction AI,

SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results13.11.2026 12:30:00 CET | Press release

Revenue Up 35%, Net Income Attributable to SBC Medical Up 22%, and Adjusted EBITDA1 Up 66% Year-over-Year; Net Income Margin of 27% and Adjusted EBITDA Margin of 47% — Previously Announced Service Fee Revisions and New Clinic Openings Contribute to Revenue Growth and Operating Margin Improvement SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the third quarter of fiscal year 2026 (the three months ended September 30, 2026) and the three cumulative quarters of fiscal year 2026 (the nine months ended September 30, 2026). Third Quarter 2026 Financial Highlights Total revenues were $59 million, up 35% year-over-year. Income from operations was $26 million, up 66% year-over-year, with an operating margin of 45%. Net income attributable to SBC Medi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye